SeaStar Medical Announces 1-for-10 Reverse Split

Core Viewpoint - SeaStar Medical Holding Corporation announced a 1-for-10 reverse stock split effective January 5, 2026, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 [1][4]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 10 pre-split shares into 1 post-split share, with stockholders receiving whole shares in lieu of any fractional shares [2]. - The reverse split will proportionately reduce the number of shares issuable upon the exercise of outstanding stock options and warrants, while also increasing their exercise prices accordingly [2]. Group 2: Stockholder Information - Stockholders will receive information regarding their share ownership from Continental Stock Transfer and Trust Company following the reverse stock split [3]. - Those holding shares through banks or brokers will have their positions automatically adjusted without needing further action [3]. Group 3: Company Overview - SeaStar Medical is focused on transforming treatments for critically ill patients facing organ failure, with its first commercial product, QUELIMMUNE (SCD-PED) therapy, approved by the FDA in 2024 for life-threatening acute kidney injury in pediatric patients [5]. - The company is conducting the NEUTRALIZE-AKI pivotal trial for its SCD therapy in adult patients, addressing a significant unmet medical need affecting over 200,000 adults in the U.S. annually [5].